Page 102 - 《中国药房》2024年23期

phase 1 cohorts from the KEYNOTE-021 study[J]. Lung [17] 刘萍，林锦培，吕旭桦，等. 信迪利单抗、贝伐珠单抗联合
Cancer，2018，125：273-281. 含铂双药化疗治疗 EGFR-TKI 耐药 NSCLC 患者的疗效
[ 8 ] RECK M，JOTTE R，MOK T S K，et al. IMpower150：an 及安全性[J]. 江苏医药，2023，49（10）：1040-1043.
exploratory analysis of efficacy outcomes in patients with LIU P，LIN J P，LYU X H，et al. The efficacy and safety
EGFR mutations[J]. Ann Oncol，2019，30：ii48-ii49. of combination therapy with platinum based dual agent
[ 9 ] BYLICKI O，CLARISSE B，GRELLARD J M，et al. chemotherapy using sintilimab and bevacizumab for
1411TiP GFPC 06-2018：a multicenter non-randomized EGFR-TKI resistant NSCLC patients [J].Jiangsu Med J，
phase Ⅱ study evaluating platinum-pemetrexed-atezoli- 2023，49（10）：1040-1043.
zumab（+/-bevacizumab） for patients with stage Ⅲ B/Ⅳ [18] 王鹏，郝朋朋，李全奎 . 一线 PD-1 单抗与贝伐单抗双靶
non-squamous non-small cell lung cancer with EGFR mu‐ 联合化疗治疗晚期非鳞非小细胞肺癌临床观察[J]. 社区
tations，ALK rearrangement or ROS1 fusion progressing 医学杂志，2023，21（20）：1052-1057.
after targeted therapies[J]. Ann Oncol，2020，31：S892. WANG P，HAO P P，LI Q K. Clinical observation of PD-1
[10] LEE J S，SUGAWARA S，KANG J H，et al. LBA54 ran‐ immunotherapy combined with the bevacizumab and the
domized phase Ⅲ trial of nivolumab in combination with chemotherapy for the advanced non-squamous non-small
carboplatin，paclitaxel，and bevacizumab as first-line treat‐ cell lung cancer[J]. J Community Med，2023，21（20）：
ment for patients with advanced or recurrent non- 1052-1057.
squamous NSCLC[J]. Ann Oncol，2020，31：S1184-S1185. [19] 郑荣香. 信迪利单抗联合贝伐珠单抗及化疗治疗晚期肺
[11] RECK M，WEHLER T，ORLANDI F，et al. Safety and 腺 癌 的 临 床 价 值 分 析 [J]. 北 方 药 学 ，2023，20（5）：
patient-reported outcomes of atezolizumab plus chemo‐ 115-117.
therapy with or without bevacizumab versus bevacizumab ZHENG R X. Clinical value of sintilimab combined with
plus chemotherapy in non-small-cell lung cancer[J]. J Clin bevacizumab and chemotherapy in the treatment of ad‐
Oncol，2020，38（22）：2530-2542. vanced lung adenocarcinoma[J]. J North Pharm，2023，20
[12] SOCINSKI M A，NISHIO M，JOTTE R M，et al. IM‐ （5）：115-117.
power150 final overall survival analyses for atezolizumab [20] HUANG Y，YANG Y P，ZHAO Y Y，et al. QL1706（anti-
plus bevacizumab and chemotherapy in first-line meta‐ PD-1 IgG4/CTLA-4 antibody） plus chemotherapy with or
static nonsquamous NSCLC[J]. J Thorac Oncol，2021，16 without bevacizumab in advanced non-small cell lung can‐
（11）：1909-1924. cer：a multi-cohort，phase Ⅱ study[J]. Signal Transduct
[13] 黄普超，张桂芳. 信迪利单抗联合贝伐珠单抗治疗晚期 Target Ther，2024，9（1）：23.
肺腺癌有效率及安全性临床观察[J]. 中国药物评价， [21] BENDELL J C，POWDERLY J D，LIEU C H，et al.
2022，39（1）：79-82. Safety and efficacy of MPDL3280A （anti-PDL1） in com‐
HUANG P C，ZHANG G F. Sindilizumab combined with bination with bevacizumab （bev） and/or FOLFOX in pa‐
bevacizumab in treatment of advanced lung adenocarci‐ tients （pts） with metastatic colorectal cancer（mCRC）[J].
noma[J]. Chin J Drug Eval，2022，39（1）：79-82. J Clin Oncol，2015，33（Suppl. 3）：704.
[14] PARK S，KIM T M，HAN J Y，et al. Phase Ⅲ，randomi- [22] WANG Y H，SHI X H，QI Q H，et al. Safety of anlotinib
zed study of atezolizumab plus bevacizumab and chemo‐ capsules combined with PD-1 inhibitor camrelizumab in
therapy in patients with EGFR- or ALK-mutated non- the third-line treatment of advanced non-small-cell lung
small-cell lung cancer（ATTLAS，KCSG-LU19-04）[J]. J cancer and their effect on serum tumor markers[J]. J
Clin Oncol，2024，42（11）：1241-1251. Healthc Eng，2021，2021：2338800.
[15] SHIRAISHI Y，KISHIMOTO J，SUGAWARA S，et al. [23] LIU Y X，ZHANG T M，ZHANG L N，et al. Combined ap‐
Atezolizumab and platinum plus pemetrexed with or with‐ plication of bevacizumab and PD-1 blockade displays du‐
out bevacizumab for metastatic nonsquamous non-small rable treatment effects by increasing the infiltration and
cell lung cancer：a phase 3 randomized clinical trial[J]. cytotoxic function of CD8 T cells in lung cancer[J]. Im‐
+
JAMA Oncol，2024，10（3）：315-324. munotherapy，2022，14（9）：695-708.
[16] 耿亭亭，张亚. 帕博利珠单抗联合标准化疗加贝伐珠单 [24] 许子宜. 非小细胞肺癌治疗模式探索及转化研究[D]. 北
抗治疗晚期非鳞非小细胞肺癌的效果[J]. 中外医药研 京：中国医学科学院，2023.
究，2023，2（13）：22-24. XU Z Y. Exploration and transformation of treatment
GENG T T，ZHANG Y. The efficacy of pembrolizumab model for non-small cell lung cancer[D]. Beijing：Chinese
combined with standard chemotherapy and bevacizumab Academy of Medical Sciences，2023.
in the treatment of advanced non-small cell lung cancer （收稿日期：2024-07-22 修回日期：2024-10-21）
[J]. Chin Foreign Med Pharm Res，2023，2（13）：22-24. （编辑：舒安琴）

· 2928 · China Pharmacy 2024 Vol. 35 No. 23 中国药房 2024年第35卷第23期